ProCE Banner Activity

How I Use Regorafenib and TAS-102 in My Patients With Metastatic CRC

Clinical Thought
Many of our patients with metastatic CRC can now plan on receiving 3 or more lines of therapy. Read how I approach sequencing and dosing with regorafenib and TAS-102 in my practice.

Released: April 24, 2019

Expiration: April 22, 2020

Share

Faculty

Tanios Bekaii-Saab

Tanios Bekaii-Saab, MD, FACP

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Professor
Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Bayer Healthcare Pharma

Taiho Oncology Inc

Partners

GRACE

ProCE Banner

Faculty Disclosure

Primary Author

Tanios Bekaii-Saab, MD, FACP

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Professor
Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has disclosed that he has received consulting fees from AbbVie, Armo, Imugene, Immuneering, and SillaJen. Dr. Bekaii-Saab also served as a consultant to Bayer, Incyte, Amgen, Merck with fees going to his institution.